BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29282688)

  • 1. Cell Cycle Regulation in Treatment of Breast Cancer.
    Cai Z; Liu Q
    Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
    DiPippo AJ; Patel NK; Barnett CM
    Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
    Akin S; Babacan T; Sarici F; Altundag K
    J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
    Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
    Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in CDK inhibitors for cancer therapy.
    Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
    Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
    Sarosiek T
    Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.